Summarized by Masters of Longevity from PR Newswire.
Eisai will present five-year Clarity AD and LEADER real-world findings.
Key Takeaways
- Five-year Clarity AD data are being presented at CTAD.
- LEADER is a retrospective multicenter real-world study in the US.
- Real-world effectiveness and safety findings were reported for lecanemab.
